(Q42987104)

12 November 2017

Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients (English)

1 reference

12 November 2017

0 references

5

1 reference

12 November 2017

9

1 reference

12 November 2017

A Iacobellis

1

0 references

author name string

M Siciliano

2

1 reference

12 November 2017

B E Annicchiarico

3

1 reference

12 November 2017

M R Valvano

4

1 reference

12 November 2017

L Accadia

6

1 reference

12 November 2017

N Caruso

7

1 reference

12 November 2017

G Bombardieri

8

1 reference

12 November 2017

language of work or name

English

0 references

publication date

17 April 2009

1 reference

Alimentary Pharmacology & Therapeutics

12 November 2017

1 reference

12 November 2017

30

1 reference

12 November 2017

2

1 reference

12 November 2017

146-153

1 reference

Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study.

12 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2009.04025.X

Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2009.04025.X

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2009.04025.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2009.04025.X

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2009.04025.X

Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2009.04025.X

Treatment of patients with hepatitis C virus on the waiting list

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2009.04025.X

Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2009.04025.X

Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2009.04025.X

A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2009.04025.X

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2009.04025.X

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2009.04025.X

Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2009.04025.X

Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2009.04025.X

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2009.04025.X

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2009.04025.X

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2009.04025.X

Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2009.04025.X

10.1111/J.1365-2036.2009.04025.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference